Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis

Kaleb D Michaud, Vibeke Strand, Nancy A. Shadick, Irina Degtiar, Kerri Ford, Steven N. Michalopoulos, John Hornberger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective. The multibiomarker disease activity (MBDA) blood test has been clinically validated as a measure of disease activity in patients with RA. We aimed to estimate the effect of the MBDA test on physical function for patients with RA (based on HAQ), quality-adjusted life years and costs over 10 years. Methods. A decision analysis was conducted to quantify the effect of using the MBDA test on RA-related outcomes and costs to private payers and employers. Results of a clinical management study reporting changes to anti-rheumatic drug recommendations after use of the MBDA test informed clinical utility. The effect of treatment changes on HAQ was derived from 5 tight-control and 13 treatment-switch trials. Baseline HAQ scores and the HAQ score relationship with medical costs and quality of life were derived from published National Data Bank for Rheumatic Diseases data. Results. Use of the MBDA test is projected to improve HAQ scores by 0.09 units in year 1, declining to 0.02 units after 10 years. Over the 10 year time horizon, quality-adjusted life years increased by 0.08 years and costs decreased by US$457 (cost savings in disability-related medical costs, US$659; in productivity costs, US$2137). The most influential variable in the analysis was the effect of the MBDA test on clinician treatment recommendations and subsequent HAQ changes. Conclusion. The MBDA test aids in the assessment of disease activity in patients with RA by changing treatment decisions, improving the functional status of patients and cost savings. Further validation is ongoing and future longitudinal studies are warranted.

Original languageEnglish (US)
Pages (from-to)1640-1649
Number of pages10
JournalRheumatology (United Kingdom)
Volume54
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

ametantrone
Rheumatoid Arthritis
Costs and Cost Analysis
Quality-Adjusted Life Years
Cost Savings
Antirheumatic Agents
Decision Support Techniques
Hematologic Tests
Therapeutics
Rheumatic Diseases
Longitudinal Studies
Quality of Life
Databases

Keywords

  • Biomarkers
  • Health economics
  • Outcome assessment
  • Quality of life
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. / Michaud, Kaleb D; Strand, Vibeke; Shadick, Nancy A.; Degtiar, Irina; Ford, Kerri; Michalopoulos, Steven N.; Hornberger, John.

In: Rheumatology (United Kingdom), Vol. 54, No. 9, 01.01.2015, p. 1640-1649.

Research output: Contribution to journalArticle

Michaud, Kaleb D ; Strand, Vibeke ; Shadick, Nancy A. ; Degtiar, Irina ; Ford, Kerri ; Michalopoulos, Steven N. ; Hornberger, John. / Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. In: Rheumatology (United Kingdom). 2015 ; Vol. 54, No. 9. pp. 1640-1649.
@article{ef03a26a6ac641488ba597f6db83e80b,
title = "Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis",
abstract = "Objective. The multibiomarker disease activity (MBDA) blood test has been clinically validated as a measure of disease activity in patients with RA. We aimed to estimate the effect of the MBDA test on physical function for patients with RA (based on HAQ), quality-adjusted life years and costs over 10 years. Methods. A decision analysis was conducted to quantify the effect of using the MBDA test on RA-related outcomes and costs to private payers and employers. Results of a clinical management study reporting changes to anti-rheumatic drug recommendations after use of the MBDA test informed clinical utility. The effect of treatment changes on HAQ was derived from 5 tight-control and 13 treatment-switch trials. Baseline HAQ scores and the HAQ score relationship with medical costs and quality of life were derived from published National Data Bank for Rheumatic Diseases data. Results. Use of the MBDA test is projected to improve HAQ scores by 0.09 units in year 1, declining to 0.02 units after 10 years. Over the 10 year time horizon, quality-adjusted life years increased by 0.08 years and costs decreased by US$457 (cost savings in disability-related medical costs, US$659; in productivity costs, US$2137). The most influential variable in the analysis was the effect of the MBDA test on clinician treatment recommendations and subsequent HAQ changes. Conclusion. The MBDA test aids in the assessment of disease activity in patients with RA by changing treatment decisions, improving the functional status of patients and cost savings. Further validation is ongoing and future longitudinal studies are warranted.",
keywords = "Biomarkers, Health economics, Outcome assessment, Quality of life, Rheumatoid arthritis",
author = "Michaud, {Kaleb D} and Vibeke Strand and Shadick, {Nancy A.} and Irina Degtiar and Kerri Ford and Michalopoulos, {Steven N.} and John Hornberger",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/rheumatology/kev023",
language = "English (US)",
volume = "54",
pages = "1640--1649",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis

AU - Michaud, Kaleb D

AU - Strand, Vibeke

AU - Shadick, Nancy A.

AU - Degtiar, Irina

AU - Ford, Kerri

AU - Michalopoulos, Steven N.

AU - Hornberger, John

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective. The multibiomarker disease activity (MBDA) blood test has been clinically validated as a measure of disease activity in patients with RA. We aimed to estimate the effect of the MBDA test on physical function for patients with RA (based on HAQ), quality-adjusted life years and costs over 10 years. Methods. A decision analysis was conducted to quantify the effect of using the MBDA test on RA-related outcomes and costs to private payers and employers. Results of a clinical management study reporting changes to anti-rheumatic drug recommendations after use of the MBDA test informed clinical utility. The effect of treatment changes on HAQ was derived from 5 tight-control and 13 treatment-switch trials. Baseline HAQ scores and the HAQ score relationship with medical costs and quality of life were derived from published National Data Bank for Rheumatic Diseases data. Results. Use of the MBDA test is projected to improve HAQ scores by 0.09 units in year 1, declining to 0.02 units after 10 years. Over the 10 year time horizon, quality-adjusted life years increased by 0.08 years and costs decreased by US$457 (cost savings in disability-related medical costs, US$659; in productivity costs, US$2137). The most influential variable in the analysis was the effect of the MBDA test on clinician treatment recommendations and subsequent HAQ changes. Conclusion. The MBDA test aids in the assessment of disease activity in patients with RA by changing treatment decisions, improving the functional status of patients and cost savings. Further validation is ongoing and future longitudinal studies are warranted.

AB - Objective. The multibiomarker disease activity (MBDA) blood test has been clinically validated as a measure of disease activity in patients with RA. We aimed to estimate the effect of the MBDA test on physical function for patients with RA (based on HAQ), quality-adjusted life years and costs over 10 years. Methods. A decision analysis was conducted to quantify the effect of using the MBDA test on RA-related outcomes and costs to private payers and employers. Results of a clinical management study reporting changes to anti-rheumatic drug recommendations after use of the MBDA test informed clinical utility. The effect of treatment changes on HAQ was derived from 5 tight-control and 13 treatment-switch trials. Baseline HAQ scores and the HAQ score relationship with medical costs and quality of life were derived from published National Data Bank for Rheumatic Diseases data. Results. Use of the MBDA test is projected to improve HAQ scores by 0.09 units in year 1, declining to 0.02 units after 10 years. Over the 10 year time horizon, quality-adjusted life years increased by 0.08 years and costs decreased by US$457 (cost savings in disability-related medical costs, US$659; in productivity costs, US$2137). The most influential variable in the analysis was the effect of the MBDA test on clinician treatment recommendations and subsequent HAQ changes. Conclusion. The MBDA test aids in the assessment of disease activity in patients with RA by changing treatment decisions, improving the functional status of patients and cost savings. Further validation is ongoing and future longitudinal studies are warranted.

KW - Biomarkers

KW - Health economics

KW - Outcome assessment

KW - Quality of life

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84943226196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943226196&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kev023

DO - 10.1093/rheumatology/kev023

M3 - Article

C2 - 25877911

AN - SCOPUS:84943226196

VL - 54

SP - 1640

EP - 1649

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 9

ER -